Drug intelligence / Profile preview

Syalox

Development stage
Unknown
Lead developer
RiverPharma
Administration
Oral
01

Overview

Syalox is a multi-ingredient nutraceutical supplement developed by River Pharma for the management of mild-to-moderate knee osteoarthritis. It is primarily available as Syalox 300 Plus, an oral tablet formulation containing 300 mg of high-molecular-weight hyaluronic acid and 100 mg of *Boswellia serrata* extract. The product leverages the synergistic effects of its components: hyaluronic acid acts as a lubricant and shock absorber within the synovial fluid while exerting anti-inflammatory effects, and *Boswellia serrata* provides potent anti-inflammatory activity by inhibiting the enzymes cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). Clinical evidence suggests that Syalox supplementation significantly reduces pain at rest and during movement and improves joint function, potentially by modulating inflammatory biomarkers such as serum adropin.

Brand names
SyaloxSyalox 300 PlusSyalox300 PlusSyalox-300 Plus
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)Eicosanoid synth (Eicosanoid biosynthesis)

Beyond the preview

Go deeper on Syalox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syalox.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call